MARKET

MAZE

MAZE

Maze Therapeutics
NASDAQ
30.38
-1.33
-4.19%
After Hours: 30.59 +0.21 +0.69% 18:39 03/27 EDT
OPEN
30.82
PREV CLOSE
31.71
HIGH
32.27
LOW
29.16
VOLUME
1.71M
TURNOVER
--
52 WEEK HIGH
53.65
52 WEEK LOW
6.71
MARKET CAP
1.51B
P/E (TTM)
-9.9574
1D
5D
1M
3M
1Y
5Y
1D
Maze Therapeutics, Inc. (MAZE) Gets a Buy from LifeSci Capital
TipRanks · 1d ago
Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
Seeking Alpha · 2d ago
Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (MAZE), Azitra Inc (AZTR) and Arrowhead Pharmaceuticals (ARWR)
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Maze Therapeutics, Inc. (MAZE) and Compass Therapeutics (CMPX)
TipRanks · 3d ago
Wedbush Reaffirms Their Buy Rating on Maze Therapeutics, Inc. (MAZE)
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Maze Therapeutics, Inc. (MAZE)
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Maze Therapeutics, Inc. (MAZE) and Daiichi Sankyo Company (OtherDSKYF)
TipRanks · 3d ago
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast
Benzinga · 4d ago
More
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Webull offers Maze Therapeutics, Inc. stock information, including NASDAQ: MAZE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MAZE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MAZE stock methods without spending real money on the virtual paper trading platform.